secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001178670-25-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam reports preliminary FY2024 net product revenues of $1.65B (+33% YoY); guides FY2025 $2.05-2.25B
--------------------------------------------------------------------------------

- Q4 2024 net product revenues ~$451M; FY2024 ~$1,646M, representing 33% annual growth.
- 2025 combined net product revenue guidance of $2.05B-$2.25B, 31% growth at mid-point vs 2024.
- TTR franchise (ONPATTRO/AMVUTTRA): FY2024 ~$1,223M; 2025 guidance $1.6B-$1.725B (36% growth).
- Rare franchise (GIVLAARI/OXLUMO): FY2024 ~$423M; 2025 guidance $450M-$525M (15% growth).
- Company expects 2025 non-GAAP operating income profitability; vutrisiran PDUFA date March 23, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000117867025000008/0001178670-25-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000117867025000008/alny-20250112.htm
  HTML page:      https://secwatch.observer/filing/0001178670-25-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer